Skip to main content

Month: May 2020

Agios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020

CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020 at 3:40 p.m. ET.A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.About AgiosAgios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular...

Continue reading

Applied Therapeutics to Present at the UBS Global Healthcare Conference

NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at the UBS Global Healthcare Conference on Monday, May 18, 2020 at 10:00 a.m. ET. The conference will be held in a virtual meeting format.Webcast information for this event will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay will also be available following the webcast.About Applied Therapeutics Inc.Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets...

Continue reading

Microbix Announces Quality Products Distribution Agreement

MISSISSAUGA, Ontario, May 12, 2020 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of Diagnostic International Distribution S.p.A. of Milan (D.I.D.) as distributor of its Quality Assessment Products (QAPs™) for Italy.Under an agreement between the parties, D.I.D. has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for Italy. As distributor, D.I.D. will provide marketing, inventorying, distribution, and logistical support for use of Microbix’s QAPs by Italian clinical laboratories. At present, there are four dozen such QAPs across the PROCEEDx™, REDx™FLOQ®, and REDx™ Controls tradenames – to support whole-process accuracy of tests for bacterial and viral diseases by emulating patient samples while being...

Continue reading

GasLog Ltd. Announces Delivery of the GasLog Wales and Commencement of 12-Year Charter with JERA

Piraeus, Greece, May 12, 2020 (GLOBE NEWSWIRE) — GasLog Ltd. (“GasLog” or “the Company”) (NYSE: GLOG) yesterday took delivery of the GasLog Wales, a 180,000 cubic meter cargo capacity LNG carrier with dual fuel medium speed propulsion (“X-DF”) and Mark III Flex Plus containment system. The vessel immediately commenced a 12-year charter with the principal LNG shipping entity of Japan’s Jera Co., Inc. (“JERA”).Paul Wogan, Chief Executive Officer of GasLog, stated “I am very pleased to announce the delivery of the GasLog Wales and commencement of her 12-year charter to JERA, one of the world’s largest LNG buyers. The vessel is the second of seven vessels we will be taking delivery of through the third quarter of 2021, representing approximately $145 million of incremental EBITDA per annum once fully delivered.I want to thank our crew,...

Continue reading

Ascot Resources Announces 2020 First Quarter Financial Results

VANCOUVER, British Columbia, May 12, 2020 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) (“Ascot” or the “Company”) announces the Company’s unaudited financial results for the three months ended March 31, 2020 (“Q1 2020”). For details of the unaudited condensed interim consolidated financial statements and Management’s Discussion and Analysis for the three months ended March 31, 2020, please see the Company’s filings on SEDAR (www.sedar.com).All amounts herein are reported in $000s of Canadian dollars (“C$”) unless otherwise specified.Q1 2020 AND RECENT HIGHLIGHTSOn January 15, 2020, the Company announced an updated Resource Estimate for the Premier Gold Project including the Silver Coin, Big Missouri and Premier deposits, representing a 60% increase in the Indicated Category (see News Release dated January...

Continue reading

IGM Biosciences to Present at the 2020 RBC Capital Markets Global Healthcare Conference

MOUNTAIN VIEW, Calif., May 12, 2020 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will present at the 2020 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19 at 4:15 p.m. ET. The conference will be held in a virtual meeting format.A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.About IGM Biosciences, Inc. Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage...

Continue reading

InspireMD Announces First Quarter 2020 Financial Results

First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major marketsManagement to host investor conference call today, May 12, at 8:30am ETTEL AVIV, Israel, May 12, 2020 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the first quarter ended March 31, 2020.First Quarter 2020 and recent highlights:Generated CGuard™ EPS revenue of $971,000, an increase of 158.2% compared to $376,000 in the first quarter of 2019, when the company’s previous third-party sterilizer equipment failures caused a significant interruption in sterilized product supply for the majority...

Continue reading

Vistin Pharma ASA: Guide for online participation at AGM

Oslo, Norway, 12 May 2020Vistin Pharma ASA (OSE: VISTIN), as previously announced Vistin Pharma ASA will be conducting this year’s Annual General Meeting on the 19 of May as a digital meeting, through Skype. This is a precautionary measure to prevent the spread of Covid-19 and to ensure the safety and wellbeing of our shareholders, employees and other stakeholders. Therefore, there will be no opportunity for physical presence this year. You may cast votes prior to the meeting or grant a proxy as in previous years. Please refer the notice for the AGM and appendices for further information on voting in advance and proxies. Attached is a stepwise guide for how to attend the meeting.The complete set of documents relating to the Annual General Meeting are available on www.vistin.com For further information, please contact:Alexander KarlsenCFO+47...

Continue reading

SRG MINING INC. ANNOUNCES GRANT OF STOCK OPTIONS

Montreal, Quebec, May 12, 2020 (GLOBE NEWSWIRE) — SRG Mining Inc. (TSXV: SRG) (“SRG” or the “Company”) is pleased to announce that, pursuant to its Stock Option Plan and subject to regulatory acceptance, it has granted an aggregate total of 1,108,493 incentive stock options to certain directors, officers and consultants of the Company, subject to certain vesting provisions.  These options will be exercisable at a price of $0.37 per common share and will expire on May 11, 2030. About SRG MiningSRG Mining is a Canadian-based mining company focused on developing the Lola graphite deposit located in the Republic of Guinea, West Africa. SRG is committed to operating in a socially, environmentally, and ethically responsible manner. For additional information, please visit SRG’s website at www.srgmining.com.  Or contact: Neither the TSXV...

Continue reading

Endeavour Silver Releases 2019 Annual Review and Sustainability Report

VANCOUVER, British Columbia, May 12, 2020 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (NYSE: EXK) (TSX: EDR) announces the publication of its 2019 Annual Review and Sustainability Report entitled “Recognizing 15 years of Mine Production.” This marks the eighth consecutive year the Company has reported on its sustainability initiatives, including the last seven under the GRI Standards for sustainability reporting.Endeavour’s 2019 Annual Review and Sustainability Report is available at https://csr.edrsilver.com or the full report can be downloaded here. The Spanish versions will be available by month-end on the company website. All dollar amounts presented below are in U.S. dollars.2019 Sustainability HighlightsSafety and Health70% of all training activities involved safety education, highlighting its importanceGuanacevi received the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.